In the HHLA2 low-expression group, lower immune scores of stromal fraction, intratumor heterogeneity, aneuploidy, and proliferation were observed, while the TGF-beta response score was increased, which suggested that high HHLA2 expression can also promote immunological responses in CRC [23,25]. This evidence concerns the gene HHLA2 and colorectal carcinoma.